Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
The analysts said GLP-1 sales could reach $102 billion by 2030, of which obesity is projected to contribute $41 billion. Two leaders in this field are expected to take roughly 44% and 52% share, respectively, of the global GLP-1 market in 2030. With high financial gain predicted, supply issues have been raised concerning how companies will meet the growing demand
doi: 10.1038/s41598-017-09898-4
Beyond product access, strong supply relationships contribute to smoother planning and improved operational consistency
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
As its predicted GLP-1 use will continue to rise in OSA patients, a common topic in discussions, according to Peters, is how GLP-1s might affect the use of other sleep apnea therapies, like CPAP, oral appliances, and hypoglossal nerve stimulation
Secondly, the sample size is relatively small, with a majority of women, which does not allow generalization to other populations
US$ 29.63
US$ 23.48
US$ 20.46
US$ 26.81
